Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein

Virology

Volumn 452-453, Issue , 2014, Pages 32-41

  Escriou, Nicolas ^a,b,c,d   Callendret, Benoît ^a,c,d   Lorin, Valérie ^a,b,c,d   Combredet, Chantal ^b,c   Marianneau, Philippe ^e   Février, Michèle ^b,c   Tangy, Frédéric ^b,c  

^a Sorbonne Paris Cité   (France)

^b INSTITUT PASTEUR   (France)

^c Institut Pasteur   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Institut Pasteur   (France)

Author keywords

Coronavirus; Measles vaccine; Severe acute respiratory syndrome; Spike glycoprotein

Indexed keywords

MEASLES VACCINE; NEUTRALIZING ANTIBODY; SECRETED SOLUBLE ECTODOMAIN PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS SPIKE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; MEASLES; MEASLES VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; SEVERE ACUTE RESPIRATORY SYNDROME; TH1 CELL; VIRUS REPLICATION;

CORONAVIRUS; MEASLES VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME; SPIKE GLYCOPROTEIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; GENETIC VECTORS; HUMANS; MALE; MEASLES VACCINE; MEASLES VIRUS; MICE; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SPIKE GLYCOPROTEIN, CORONAVIRUS; TH1 CELLS; VIRAL VACCINES;

EID: 84893124445     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.01.002     Document Type: Article

References (81)

1. Balboni A., Battilani M., Prosperi S. The SARS-like coronaviruses: the role of bats and evolutionary relationships with SARS coronavirus. N. Microbiol. 2012, 35:1-16.
2. Bellanti J.A., Zeligs B.J., Mendez-Inocencio J., Garcia-Garcia M.L., Islas-Romero R., Omidvar B., Omidvar J., Kim G., Fernandez De Castro J., Sepulveda Amor J., Walls L., Bellini W.J., Valdespino-Gomez J.L. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 2004, 22:1214-1220.
3. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., Subbarao K., Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA 2004, 101:6641-6646.
4. Bisht H., Roberts A., Vogel L., Subbarao K., Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 2005, 334:160-165.
5. Bolles M., Deming D., Long K., Agnihothram S., Whitmore A., Ferris M., Funkhouser W., Gralinski L., Totura A., Heise M., Baric R.S. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 2011, 85:12201-12215.
6. Brandler S., Lucas-Hourani M., Moris A., Frenkiel M.P., Combredet C., Fevrier M., Bedouelle H., Schwartz O., Despres P., Tangy F. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl. Trop. Dis. 2007, 1:e96.
7. Brandler S., Marianneau P., Loth P., Lacote S., Combredet C., Frenkiel M.P., Despres P., Contamin H., Tangy F. Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. J. Infect. Dis. 2012, 206:212-219.
8. Brandler S., Ruffie C., Combredet C., Brault J.B., Najburg V., Prevost M.C., Habel A., Tauber E., Despres P., Tangy F. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 2013, 31:3718-3725.
9. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., Collins P.L. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA 2004, 101:9804-9809.
10. Calain P., Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J. Virol. 1993, 67:4822-4830.
11. Callendret B., Lorin V., Charneau P., Marianneau P., Contamin H., Betton J.-M., van der Werf S., Escriou N. Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS. Virology 2007, 363:288-302.
12. Callendret B., Lorin V., Marianneau P., Contamin H., Rose T., Huerre M., van der Werf S., Charneau P., Escriou N., Efficient protection from SARS coronavirus infection conferred by a recombinant spike glycoprotein expressed as a soluble polypeptide in stable mammalian cell lines, Unpublished results.
13. Centers for Disease Control Prevention, 2009. Global measles mortality, 2000-2008. MMWR, Morbidity and Mortality Weekly Report, vol. 58, pp. 1321-1326.
14. Chen Z., Zhang L., Qin C., Ba L., Yi C.E., Zhang F., Wei Q., He T., Yu W., Yu J., Gao H., Tu X., Gettie A., Farzan M., Yuen K.Y., Ho D.D. Recombinant modified vaccinia virus ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 2005, 79:2678-2688.
15. Cheng Y., Wong R., Soo Y.O., Wong W.S., Lee C.K., Ng M.H., Chan P., Wong K.C., Leung C.B., Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 2005, 24:44-46.
16. Combredet C., Labrousse V., Mollet L., Lorin C., Delebecque F., Hurtrel B., McClure H., Feinberg M.B., Brahic M., Tangy F. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J. Virol. 2003, 77:11546-11554.
17. Cottrell S., Roberts R.J. Measles outbreak in Europe. BMJ - Br. Med. J. 2011, 342:d3724.
18. Davenport T.M., Friend D., Ellingson K., Xu H., Caldwell Z., Sellhorn G., Kraft Z., Strong R.K., Stamatatos L. Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. J. Virol. 2011, 85:7095-7107.
19. Deming D., Sheahan T., Heise M., Yount B., Davis N., Sims A., Suthar M., Harkema J., Whitmore A., Pickles R., West A., Donaldson E., Curtis K., Johnston R., Baric R. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006, 3:e525.
20. Despres P., Combredet C., Frenkiel M.P., Lorin C., Brahic M., Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J. Infect. Dis. 2005, 191:207-214.
21. Dilraj A., Cutts F.T., Bennett J.V., Fernandez de Castro J., Cohen B., Coovadia H.M. Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes. Pediatr. Infect. Dis. J. 2000, 19:1211-1213.
22. Drosten C., Chiu L.L., Panning M., Leong H.N., Preiser W., Tam J.S., Gunther S., Kramme S., Emmerich P., Ng W.L., Schmitz H., Koay E.S. Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus. J. Clin. Microbiol. 2004, 42:2043-2047.
23. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348:1967-1976.
24. Du L., He Y., Jiang S., Zheng B.J. Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc.) 2008, 44:63-73.
25. Enjuanes L., Dediego M.L., Alvarez E., Deming D., Sheahan T., Baric R. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 2008, 133:45-62.
26. Fett C., DeDiego M.L., Regla-Nava J.A., Enjuanes L., Perlman S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J. Virol. 2013, 87:6551-6559.
27. Frieman M.B., Chen J., Morrison T.E., Whitmore A., Funkhouser W., Ward J.M., Lamirande E.W., Roberts A., Heise M., Subbarao K., Baric R.S. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 2010, 6:e1000849.
28. Gans H., DeHovitz R., Forghani B., Beeler J., Maldonado Y., Arvin A.M. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 2003, 21:3398-3405.
29. Gans H., Yasukawa L., Rinki M., DeHovitz R., Forghani B., Beeler J., Audet S., Maldonado Y., Arvin A.M. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J. Infect. Dis. 2001, 184:817-826.
30. Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W., Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W., Shortridge K.F., Yuen K.Y., Peiris J.S., Poon L.L. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302:276-278.
31. Guerbois M., Moris A., Combredet C., Najburg V., Ruffie C., Fevrier M., Cayet N., Brandler S., Schwartz O., Tangy F. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 2009, 388:191-203.
32. He Y., Li J., Heck S., Lustigman S., Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J. Virol. 2006, 80:5757-5767.
33. He Y., Zhu Q., Liu S., Zhou Y., Yang B., Li J., Jiang S. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 2005, 334:74-82.
34. Hogan R.J., Gao G., Rowe T., Bell P., Flieder D., Paragas J., Kobinger G.P., Wivel N.A., Crystal R.G., Boyer J., Feldmann H., Voss T.G., Wilson J.M. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J. Virol. 2004, 78:11416-11421.
35. Kan B., Wang M., Jing H., Xu H., Jiang X., Yan M., Liang W., Zheng H., Wan K., Liu Q., Cui B., Xu Y., Zhang E., Wang H., Ye J., Li G., Li M., Cui Z., Qi X., Chen K., Du L., Gao K., Zhao Y.T., Zou X.Z., Feng Y.J., Gao Y.F., Hai R., Yu D., Guan Y., Xu J. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J. Virol. 2005, 79:11892-11900.
36. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005, 340:174-182.
37. Kovacs J.M., Nkolola J.P., Peng H., Cheung A., Perry J., Miller C.A., Seaman M.S., Barouch D.H., Chen B. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc. Natl. Acad. Sci. USA 2012, 109:12111-12116.
38. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348:1953-1966.
39. Lamb R.A., Kolakofsky D. Paramyxoviridae: the viruses and their replication. Fields Virology 2001, Lippincott Williams & Wilkins, Philadelphia, PA. 4th ed. D.M. Knipe, P.M. Howley (Eds.).
40. Lamirande E.W., DeDiego M.L., Roberts A., Jackson J.P., Alvarez E., Sheahan T., Shieh W.J., Zaki S.R., Baric R., Enjuanes L., Subbarao K. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J. Virol. 2008, 82:7721-7724.
41. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426:450-454.
42. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., Wang H., Crameri G., Hu Z., Zhang H., Zhang J., McEachern J., Field H., Daszak P., Eaton B.T., Zhang S., Wang L.F. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005, 310:676-679.
43. Liniger M., Zuniga A., Tamin A., Azzouz-Morin T.N., Knuchel M., Marty R.R., Wiegand M., Weibel S., Kelvin D., Rota P.A., Naim H.Y. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 2008, 26:2164-2174.
44. Lorin C., Mollet L., Delebecque F., Combredet C., Hurtrel B., Charneau P., Brahic M., Tangy F. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 2004, 78:146-157.
45. Lorin C., Segal L., Mols J., Morelle D., Bourguignon P., Rovira O., Mettens P., Silvano J., Dumey N., Le Goff F., Koutsoukos M., Voss G., Tangy F. Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques. Naunyn-Schmiedeberg's Arch. Pharmacol. 2012, 385:1211-1225.
46. Matsuyama S., Nagata N., Shirato K., Kawase M., Takeda M., Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 2010, 84:12658-12664.
47. Miyoshi-Akiyama T., Ishida I., Fukushi M., Yamaguchi K., Matsuoka Y., Ishihara T., Tsukahara M., Hatakeyama S., Itoh N., Morisawa A., Yoshinaka Y., Yamamoto N., Lianfeng Z., Chuan Q., Kirikae T., Sasazuki T. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. J. Infect. Dis. 2011, 203:1574-1581.
48. Mrkic B., Pavlovic J., Rulicke T., Volpe P., Buchholz C.J., Hourcade D., Atkinson J.P., Aguzzi A., Cattaneo R. Measles virus spread and pathogenesis in genetically modified mice. J. Virol. 1998, 72:7420-7427.
49. Neuman B.W., Adair B.D., Yoshioka C., Quispe J.D., Orca G., Kuhn P., Milligan R.A., Yeager M., Buchmeier M.J. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J. Virol. 2006, 80:7918-7928.
50. Nie Y., Wang G., Shi X., Zhang H., Qiu Y., He Z., Wang W., Lian G., Yin X., Du L., Ren L., Wang J., He X., Li T., Deng H., Ding M. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J. Infect. Dis. 2004, 190:1119-1126.
51. Perlman S. The middle East respiratory syndrome - how worried should we be?. mBio 2013, 4:e00531-13.
52. Petit C.M., Melancon J.M., Chouljenko V.N., Colgrove R., Farzan M., Knipe D.M., Kousoulas K.G. Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion. Virology 2005, 341:215-230.
53. Rager-Zisman B., Bazarsky E., Skibin A., Chamney S., Belmaker I., Shai I., Kordysh E., Griffin D.E. The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine 2003, 21:2580-2588.
54. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
55. Roberts A., Lamirande E.W., Vogel L., Jackson J.P., Paddock C.D., Guarner J., Zaki S.R., Sheahan T., Baric R., Subbarao K. Animal models and vaccines for SARS-CoV infection. Virus Res. 2008, 133:20-32.
56. Roberts A., Thomas W.D., Guarner J., Lamirande E.W., Babcock G.J., Greenough T.C., Vogel L., Hayes N., Sullivan J.L., Zaki S., Subbarao K., Ambrosino D.M. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J. Infect. Dis. 2006, 193:685-692.
57. Roper R.L., Rehm K.E. SARS vaccines: where are we?. Expert Rev. Vaccines 2009, 8:887-898.
58. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300:1394-1399.
59. Schneider H., Kaelin K., Billeter M.A. Recombinant measles viruses defective for RNA editing and V protein synthesis are viable in cultured cells. Virology 1997, 227:314-322.
60. Sepulveda-Amor J., Valdespino-Gomez J.L., Garcia-Garcia Mde L., Bennett J., Islas-Romero R., Echaniz-Aviles G., de Castro J.F. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002, 20:2790-2795.
61. Sheahan T., Whitmore A., Long K., Ferris M., Rockx B., Funkhouser W., Donaldson E., Gralinski L., Collier M., Heise M., Davis N., Johnston R., Baric R.S. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J. Virol. 2011, 85:217-230.
62. Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA 2005, 102:11876-11881.
63. Simon J.K., Ramirez K., Cuberos L., Campbell J.D., Viret J.F., Munoz A., Lagos R., Levine M.M., Pasetti M.F. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clin. Vaccine Immunol.: CVI 2011, 18:355-361.
64. Song H.C., Seo M.Y., Stadler K., Yoo B.J., Choo Q.L., Coates S.R., Uematsu Y., Harada T., Greer C.E., Polo J.M., Pileri P., Eickmann M., Rappuoli R., Abrignani S., Houghton M., Han J.H. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J. Virol. 2004, 78:10328-10335.
65. Song H.D., Tu C.C., Zhang G.W., Wang S.Y., Zheng K., Lei L.C., Chen Q.X., Gao Y.W., Zhou H.Q., Xiang H., Zheng H.J., Chern S.W., Cheng F., Pan C.M., Xuan H., Chen S.J., Luo H.M., Zhou D.H., Liu Y.F., He J.F., Qin P.Z., Li L.H., Ren Y.Q., Liang W.J., Yu Y.D., Anderson L., Wang M., Xu R.H., Wu X.W., Zheng H.Y., Chen J.D., Liang G., Gao Y., Liao M., Fang L., Jiang L.Y., Li H., Chen F., Di B., He L.J., Lin J.Y., Tong S., Kong X., Du L., Hao P., Tang H., Bernini A., Yu X.J., Spiga O., Guo Z.M., Pan H.Y., He W.Z., Manuguerra J.C., Fontanet A., Danchin A., Niccolai N., Li Y.X., Wu C.I., Zhao G.P. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc. Natl. Acad. Sci. USA 2005, 102:2430-2435.
66. Stadler K., Roberts A., Becker S., Vogel L., Eickmann M., Kolesnikova L., Klenk H.D., Murphy B., Rappuoli R., Abrignani S., Subbarao K. SARS vaccine protective in mice. Emerg. Infect. Dis. 2005, 11:1312-1314.
67. Stebbings R., Fevrier M., Li B., Lorin C., Koutsoukos M., Mee E., Rose N., Hall J., Page M., Almond N., Voss G., Tangy F. Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PloS One 2012, 7:e50397.
68. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., Custers J.H., Popernack P.M., Yang Z.Y., Pau M.G., Roederer M., Koup R.A., Goudsmit J., Jahrling P.B., Nabel G.J. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006, 3:e177.
69. Tangy F., Naim H.Y. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol. 2005, 18:317-326.
70. ter Meulen J., Bakker A.B., van den Brink E.N., Weverling G.J., Martina B.E., Haagmans B.L., Kuiken T., de Kruif J., Preiser W., Spaan W., Gelderblom H.R., Goudsmit J., Osterhaus A.D. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004, 363:2139-2141.
71. Tripp R.A., Haynes L.M., Moore D., Anderson B., Tamin A., Harcourt B.H., Jones L.P., Yilla M., Babcock G.J., Greenough T., Ambrosino D.M., Alvarez R., Callaway J., Cavitt S., Kamrud K., Alterson H., Smith J., Harcourt J.L., Miao C., Razdan R., Comer J.A., Rollin P.E., Ksiazek T.G., Sanchez A., Rota P.A., Bellini W.J., Anderson L.J. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J. Virol. Methods 2005, 128:21-28.
72. Tseng C.T., Sbrana E., Iwata-Yoshikawa N., Newman P.C., Garron T., Atmar R.L., Peters C.J., Couch R.B. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS One 2012, 7:e35421.
73. WHO, 2004. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. (accessed 29.08.2013). http://www.who.int/csr/sars/country/table2004_04_21/en/index.html.
74. WHO, 2013. Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update - as of 13 August 2013. (accessed 29.08.2013). http://www.who.int/csr/disease/coronavirus_infections/update_20130813.
75. Wong S.K., Li W., Moore M.J., Choe H., Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 2004, 279:3197-3201.
76. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., Nabel G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428:561-564.
77. Yang Z.Y., Werner H.C., Kong W.P., Leung K., Traggiai E., Lanzavecchia A., Nabel G.J. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl. Acad. Sci. USA 2005, 102:797-801.
78. Yeh K.M., Chiueh T.S., Siu L.K., Lin J.C., Chan P.K., Peng M.Y., Wan H.L., Chen J.H., Hu B.S., Perng C.L., Lu J.J., Chang F.Y. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J. Antimicrob. Chemother. 2005, 56:919-922.
79. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367:1814-1820.
80. Zhou J., Wang W., Zhong Q., Hou W., Yang Z., Xiao S.Y., Zhu R., Tang Z., Wang Y., Xian Q., Tang H., Wen L. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 2005, 23:3202-3209.
81. Zhou Z., Post P., Chubet R., Holtz K., McPherson C., Petric M., Cox M. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 2006, 24:3624-3631.